retatrutide triple agonist glp-1 gip glucagon phase 3 2025 Eli Lilly's shows promising weight loss results in trial Lilly's triple agonist achieves 16.8%
Description
Psychiatry 163, 19051917
Science 387 , 329336 (2025)
Accessed Dec 2024
Microglia states and nomenclature: a field at its crossroads
Conclusion In recent years, clinical guidelines have begun to emphasize the importance of diabetes-related NDs and their risk of cognitive impairment, despite widespread concerns
